Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Share-based Compensation (2016 - 2025)

Adma Biologics (ADMA) has disclosed Share-based Compensation for 13 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 0.75% year-over-year to $5.4 million, compared with a TTM value of $20.0 million through Dec 2025, up 47.08%, and an annual FY2025 reading of $20.0 million, up 47.08% over the prior year.
  • Share-based Compensation was $5.4 million for Q4 2025 at Adma Biologics, up from $5.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $5.4 million in Q4 2024 and bottomed at $688274.0 in Q3 2021.
  • Average Share-based Compensation over 5 years is $2.4 million, with a median of $1.7 million recorded in 2022.
  • The sharpest move saw Share-based Compensation plummeted 32.37% in 2023, then soared 211.35% in 2024.
  • Year by year, Share-based Compensation stood at $1.2 million in 2021, then decreased by 11.88% to $1.1 million in 2022, then skyrocketed by 63.22% to $1.7 million in 2023, then skyrocketed by 211.35% to $5.4 million in 2024, then dropped by 0.75% to $5.4 million in 2025.
  • Business Quant data shows Share-based Compensation for ADMA at $5.4 million in Q4 2025, $5.0 million in Q3 2025, and $5.0 million in Q2 2025.